We are live on ! Find out more
VAM

Visium Asset Management Portfolio holdings

AUM $1.43B
1-Year Est. Return 3.58%
This Fund
S&P 500
This Quarter Est. Return
+4.67%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.05B
AUM Growth
+$276M
Cap. Flow
+$73M
Cap. Flow %
1.04%
Top 10 Hldgs %
27.96%
Holding
1,430
New
433
Increased
334
Reduced
305
Closed
319

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$182M
2
ENDP
Endo International plc
ENDP
+$170M
3
AET
Aetna Inc
AET
+$131M
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$108M
5
BKD icon
Brookdale Senior Living
BKD
+$91.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$435M
2
ELV icon
Elevance Health
ELV
+$121M
3
CI icon
Cigna
CI
+$119M
4
WMGI
Wright Medical Group Inc
WMGI
+$82.7M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$72.8M

Sector Composition

Rank Sector Weight
1 Healthcare 49.34%
2 Financials 7.86%
3 Consumer Discretionary 7.17%
4 Technology 6.32%
5 Industrials 4.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
1
Labcorp
LH
$25B
$409M 5.8%
3,926,898
+152,833
+4% +$15.9M
PRGO icon
2
Perrigo
PRGO
$1.4B
$387M 5.48%
2,091,441
+92,885
+5% +$17.7M
ENDP
3
DELISTED
Endo International plc
ENDP
$296M 4.19%
3,710,724
+1,970,035
+113% +$170M
BHC icon
4
Bausch Health
BHC
$2.58B
$185M 2.62%
831,417
+822,217
+8,937% +$182M
AET
5
DELISTED
Aetna Inc
AET
$157M 2.22%
1,230,267
+1,144,373
+1,332% +$131M
CNMD icon
6
CONMED
CNMD
$1.39B
$136M 1.93%
2,340,000
+763,132
+48% +$41.1M
ZBH icon
7
Zimmer Biomet
ZBH
$18.2B
$109M 1.55%
1,032,532
+482,575
+88% +$53.4M
SIOX
8
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$104M 1.47%
+635,000
New +$108M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.8B
$95.9M 1.36%
2,007,183
-1,012,694
-34% -$42.9M
MNTA
10
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$94.5M 1.34%
4,141,100
+2,761,090
+200% +$55M
BKD icon
11
Brookdale Senior Living
BKD
$3.49B
$86M 1.22%
+2,478,978
New +$91.4M
HR icon
12
Healthcare Realty
HR
$7.28B
$69M 0.98%
2,882,099
+291,449
+11% +$7.45M
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.45B
$68.4M 0.97%
668,238
-69,258
-9% -$5.38M
CLVS
14
DELISTED
Clovis Oncology, Inc.
CLVS
$66M 0.94%
750,823
+93,831
+14% +$8.03M
AMRI
15
DELISTED
Albany Molecular Research Inc
AMRI
$64.7M 0.92%
3,200,000
+1,820,000
+132% +$35.1M
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
$64.7M 0.92%
791,157
-612,443
-44% -$60M
ALGN icon
17
Align Technology
ALGN
$12.1B
$63.5M 0.9%
1,012,042
+188,142
+23% +$11.1M
MCK icon
18
McKesson
MCK
$100B
$61.5M 0.87%
273,375
+119,949
+78% +$27.7M
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$58.5M 0.83%
1,683,700
-1,276,846
-43% -$39M
CBPO
20
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$57.6M 0.82%
500,259
+62,251
+14% +$6.54M
BCR
21
DELISTED
CR Bard Inc.
BCR
$56.3M 0.8%
329,616
+132,882
+68% +$22.7M
EW icon
22
Edwards Lifesciences
EW
$49.6B
$55.2M 0.78%
2,326,338
+2,229,432
+2,301% +$50.3M
PRTA icon
23
Prothena Corp
PRTA
$425M
$52.5M 0.74%
996,887
+694,848
+230% +$27.4M
RCPT
24
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$49.4M 0.7%
260,090
-120,117
-32% -$19.8M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$48M 0.68%
656,921
+631,921
+2,528% +$40.6M
1
2 3 4 5

Similar funds

FBNAT
FirstMerit Bank N.A. Trustee Akron, Ohio $1.24B AUM 5.12% 1-Year Est. Return
CPS
Counsel Portfolio Services Mississauga, Ontario, Canada $1.01B AUM 2.83% 1-Year Est. Return
LH
Lebenthal Holdings New York $806M AUM 2.13% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
VFS
VSR Financial Services Overland Park, Kansas $607M AUM 0.85% 1-Year Est. Return
ZA
Zweig Advisers Hartford, Connecticut $586M AUM 1.34% 1-Year Est. Return
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
WA
Westport Advisers Westport, Connecticut $542M AUM 2.07% 1-Year Est. Return

Visium Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Visium Asset Management held 1,430 positions worth $7.05B, up 4.1% from $6.78B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Visium Asset Management's Q2 2015 filing shows 433 new, 334 increased, 305 reduced and 319 closed positions. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 635,000 shares worth $104M. The largest sale was Allergan plc, an estimated $435M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 49% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Visium Asset Management's largest Q2 2015 buy was Sio Gene Therapies Inc. Common Stock: 635,000 shares worth $104M.
  • Visium Asset Management added most to Bausch Health in Q2 2015, an estimated $182M increase.
  • Visium Asset Management's biggest Q2 2015 reduction was Elevance Health, cutting an estimated $121M.
  • Visium Asset Management fully exited Allergan plc in Q2 2015, selling an estimated $435M.
  • Visium Asset Management's ten largest holdings make up 28% of its $7.05B portfolio in Q2 2015.
  • Visium Asset Management opened 433 new positions and closed 319 in Q2 2015.
  • Visium Asset Management's portfolio value rose 4.1% quarter-over-quarter to $7.05B.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.